CORE--HYBRIDOMA FACILITY

混合动力核心设施将由大约30个UM-MAC使用 研究人员正在进行各种研究项目， 克隆抗体杂交瘤设施（HF）是一项研究， 实验室，其目的是产生体细胞杂交 （杂交瘤）产生所需特异性的单克隆抗体。它 由密歇根糖尿病研究和培训中心支持 （MDRTC）和密歇根大学多功能关节炎中心（University of Michigan Multipurpose Arthritis Center） （UM-MAC），供这些中心内的研究者使用，目前在 充电10%。它也被其他调查人员在完全充电时使用 基础服务包括小鼠免疫接种、B淋巴细胞与 骨髓瘤细胞产生杂交瘤，亚克隆和冷冻保存 杂交瘤、抗体同种型和小鼠腹水的产生。 咨询可从混合核心董事在设计 免疫策略和筛查检测，以确保有效检测 所需的单克隆抗体。大多数杂交瘤产生的 核心中的杂交瘤是鼠源性的，但大鼠、仓鼠和人杂交瘤 也被生产出来。自1980年成立以来， 该设施已经生产了针对各种各样的单克隆抗体， 淋巴细胞表面抗原，肿瘤细胞抗原，纯化蛋白， 激素、激素受体和重组蛋白质。过去四 1993年至1996年，在UM-MAC支持下，进行了超过65次融合 对UM-MAC调查员来说。对超过350个细胞进行亚克隆， 杂交瘤和近400个单克隆抗体批次生产， 小鼠腹水。在此期间，增加了各种专门程序， 目前的资金周期，以满足各种需求的UM-MAC investigators. 目前的建议将允许该设施继续提供- UM-MAC实验室的最新杂交瘤技术。核心还将 为UM-MAC矢量核心提供协作和咨询服务 协助可能希望选择重组抗体的研究者- 如来自噬菌体展示文库的试剂。通过这些举措， 杂交瘤核心将保持在单克隆抗体的前沿 技术，并继续为UM-MAC提供最佳服务 investigators.

The Hybridoma Core Facility will be used by approximately 30 UM-MAC investigators who are pursuing a variety of research projects that require monoclonal antibodies. The hybridoma Facility (HF) is a research laboratory, the purpose of which is to generate somatic-cell hybrids (hybridomas) that produce monoclonal antibodies of desired specificity. It is supported by the Michigan Diabetes Research and Training Center (MDRTC), and by the University of Michigan Multipurpose Arthritis Center (UM-MAC), for use by investigators within these centers, currently at a 10% recharge. It is also used by other investigators on a full recharge basis. Services include immunization of mice, fusion of B lymphocytes with myeloma cells to create hybridomas, subcloning and cryopreservation of hybridomas, antibody isotyping and production of ascites in mice. Consultation is available from the Hybridoma Core directors in design of immunization strategies and screening assays to ensure efficient detection of the desired monoclonal antibodies. The majority of hybridomas produced in the core are of murine origin, but rat, hamster and human hybridomas have also been produced. Since its establishment in 1980 the Hybridoma Facility has produced monoclonal antibodies against a wide variety of lymphocyte surface antigens, tumor cell antigens, purified proteins, hormones, hormone receptors and recombinant proteins. In the past four years of UM-MAC support (1993-1996) more than 65 fusions were performed for UM-MAC investigators. Subcloning was performed for more than 350 hybridomas and almost 400 monoclonal antibody batches were produced in murine ascites. A variety of specialized procedures have been added during the current funding cycle to address various needs of UM-MAC investigators. The current proposal will allow this facility to continue to provide up- to-date hybridoma technology for UM-MAC laboratories. The core will also provide collaborative and consultive services for the UM-MAC vector core in assisting investigators who may wish to select recombinant antibody- like reagents from phage display libraries. Through these initiatives, the Hybridoma Core will remain on the cutting edge of monoclonal antibody technology, and continue to provide optimal service to UM-MAC investigators.